3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
4
Phase 2/3
3
Phase 1
3
Phase NA
1
Status
Recruiting
2
Not yet recruiting
1
Sponsor Class
OTHER
3
Study Type
Interventional
3
Sponsor
Cancer Type
Other hematologic neoplasm
23
Lymphoid
8
Myeloid
6
CNS
5
Plasma cell
4
Gastrointestinal
4
Thoracic
3
Head & Neck
3
Gynecologic
3
Dermatologic
3
Genitourinary
2
Endocrine
2
Sarcoma
1
Conditions
Ovarian Neoplasms
26
Uterine Cervical Neoplasms
16
Endometrial Neoplasms
14
Fallopian Tube Neoplasms
10
Carcinoma, Ovarian Epithelial
7
Colorectal Neoplasms
6
Peritoneal Neoplasms
5
Neoplasms
5
Uterine Cervical Dysplasia
4
Lung Neoplasms
4
Gestational Trophoblastic Disease
4
Pancreatic Neoplasms
3
Neoplasms by Site
3
Neoplasms by Histologic Type
3
Melanoma
3
Hematologic Neoplasms
3
Endometrial Hyperplasia
3
Urinary Bladder Neoplasms
2
Thyroid Carcinoma, Anaplastic
2
Thyroid Cancer, Papillary
2
Stomach Neoplasms
2
Prostatic Neoplasms
2
Progesterone Resistance
2
Ovarian Cysts
2
Obesity
2
Multiple Myeloma
2
Lymphoproliferative Disorders
2
Laryngeal Neoplasms
2
Head and Neck Neoplasms
2
Glioma
2
Interventions
trametinib
1
pertuzumab
1
dabrafenib
1
cobimetinib
1
Vemurafenib
1
Trastuzumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
3 trials
Recent
Start date
Enrollment
Phase 2/3
×
Hematologic Neoplasms
×
Gynecologic
×
Clear all
NCT07440290
2026-02-27
DETERMINE
Cancer Research UK
Phase 2/3
Not yet recruiting
30 enrolled
NCT05786716
2025-12-02
DETERMINE
Cancer Research UK
Phase 2/3
Recruiting
30 enrolled
NCT05768178
2025-11-24
DETERMINE
Cancer Research UK
Phase 2/3
Recruiting
30 enrolled